News & Updates

The osteoporosis drug alendronate halves the risk of developing type 2 diabetes (T2D) in a nationwide, retrospective, case-control study of nearly 700,000 patients from Denmark.

Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

Dual antiplatelet therapy (DAPT) with cilostazol performs better than either aspirin or clopidogrel alone at reducing the risk of recurrent stroke or vascular events without increasing the incidence of bleeding for patients with ischaemic stroke and intracranial arterial stenosis, according to the results of the CSPS.com* trial.

Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.

Monotherapy with ticagrelor after a month-long course of dual antiplatelet (DAPT) with ticagrelor plus aspirin works to reduce the risk of bleeding without compromising ischaemic outcomes among patients with acute coronary syndrome (ACS) as compared with guideline-recommended treatment with 12-month DAPT followed by aspirin monotherapy, according to data from the GLOBAL LEADERS trial.

Use of linaclotide results in a significant reduction in several abdominal symptoms, such as bloating, discomfort, and pain, among patients with constipation-predominant irritable bowel syndrome (IBS-C) as compared with placebo, according to a study. In addition, reported adverse events (AEs) are in line with the established safety profile.

Patients on sodium-glucose co-transporter (SGLT) 2 inhibitors are less likely to develop asthma compared with those on dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), a study has found.